Dr. Mark Heaney is a hematologist and an active principal investigator of several clinical trials that have aimed at developing novel treatments for leukemia. His research has focused on metabolic differences between leukemia cells and normal cells that can provide understanding into how leukemias behave in the individual patient and how they respond to treatment. He chiefly focussed on the new treatments of the myeloproliferative neoplasms, primary myelofibrosis, polycythemia vera and essential thrombocythemia, however, has also studied new treatments for chronic myeloid leukemia, mastocytosis and Langerhans cell histiocytosis in keeping with his clinical expertise in rare blood cancers. He currently serves as Professor of Medicine and Director of Hematology and Medical Oncology Fellowship Program at Columbia University Medical Center.